At admission, MASLD patients displayed an altered systemic cytokine profile, with significantly elevated IL-17A, IL-2, CXCL10, TGF-β1 and IL-10. This evidence concerns the gene TGFB1 and metabolic dysfunction-associated steatotic liver disease.